SCHEMBL4980596

SCHEMBL4980596

COc1cccc(OCc2ccccc2)c1CC=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 9/20 0.53
ADRA1D P25100 8/20 0.53
ADRA1A P35348 8/20 0.53
ADRA1B P35368 8/20 0.53
MAPT P10636 1/20 0.51
MAPK1 P28482 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
MRGPRX4 Q96LA9 1/20 0.49
RXRA P19793 1/20 0.49
BCHE P06276 3/20 0.48
ATM Q13315 1/20 0.48
CCNB2 O95067 1/20 0.48
CDK1 P06493 1/20 0.48
CDK4 P11802 1/20 0.48
CCNB1 P14635 1/20 0.48
CCND1 P24385 1/20 0.48
CCNB3 Q8WWL7 1/20 0.48
ERN1 O75460 1/20 0.47
APP P05067 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7019519 0.92 MAPT (0.55) HTR1AADRA1DADRA1AADRA1BMAPT
SCHEMBL2489060 0.88 HTR1A (0.52) HTR1AADRA1DADRA1AADRA1BTDP1
SCHEMBL3128179 0.83 TLR2 (0.46) MAPTMAPK1ERN1
SCHEMBL16151391 0.82 HTR1A (0.51) HTR1AADRA1DADRA1AADRA1BMAPT
SCHEMBL8699251 0.81 HCRTR1 (0.41) MAPTTDP1L3MBTL1ERN1
SCHEMBL27998855 0.80 PDE4A (0.47) HTR1AADRA1DADRA1AADRA1BMAPK1
SCHEMBL7019839 0.80 CCNB2 (0.43) HTR1AMAPTMAPK1TDP1L3MBTL1
SCHEMBL2575268 0.80 L3MBTL1 (0.56) HTR1AADRA1DADRA1AADRA1BMAPT
SCHEMBL3950505 0.79 PTGER4 (0.62) MAPTBCHEAPPABCB1
SCHEMBL6034660 0.79 RXRA (0.56) HTR1AADRA1DADRA1AADRA1BMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080119518-A1 1-(Piperidin-4- Yl)-1H-Indole Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-05-22 US disclosed
US-20080119518-A1 1-(Piperidin-4- Yl)-1H-Indole Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-05-22 US disclosed
US-20080119518-A1 1-(Piperidin-4- Yl)-1H-Indole Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-05-22 US disclosed
EP-1847535-A1 1-(PIPERIDIN-4-YL)-1H-INDOLE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2007-10-24 EP disclosed
EP-1847535-A1 1-(PIPERIDIN-4-YL)-1H-INDOLE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119518-A1 1-(Piperidin-4- Yl)-1H-Indole Derivatives TPH1, HTR1D, HTR1B HTR1A 4/4885ADRA1D 18/4885ADRA1A 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.